EML4

EML4

A gene on chromosome 2p21 that encodes echinoderm microtubule-associated protein-like 4, which is thought to modify the assembly dynamics of microtubules.
Mentioned in ?
References in periodicals archive ?
Various ALK gene arrangements, or translocations, have been observed in NSCLC; the majority of variants involve gene fusions between the ALK and EML4 genes.
Chou y colaboradores [1] sugieren que en estudios recientes han demostrado que algunos CPT llevan un gen de fusion oncogenica causada por translocacion del gen cinasa del linfoma anaplasico (ALK) con varios socios, incluyendo EML4 limitado, GFT y GTF2IRD1, y hasta la fecha solo se han identificado en los CPT y carcinomas pobremente diferenciados y anaplasico (presumiblemente derivados de diferenciacion del CPT) que sugieren que las translocaciones ALK pueden ser mas comun en los subtipos agresivos de CPT.
7) EML4 encodes a microtubule-associated protein with a coiled-coil domain, and ALK encodes a receptor-type protein tyrosine kinase.
8) Human genes: ERBB2 (also known as HER2), v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; EML4, echinoderm microtubule associated protein like 4; ALK, anaplastic lymphoma receptor tyrosine kinase; BRAF, B-Raf proto-oncogene, serine/threonine kinase; EGFR, epidermal growth factor receptor.
Tal es el caso de un estudio reciente que demostro la eficacia de crizotinib por via oral para un subgrupo (2-7%) de pacientes con cancer pulmonar de celulas no pequenas en cuyo ADN tienen una mutacion causada por la fusion anomala de dos genes: EML4 y ALK (http://goo.
In some patients with non-small cell lung cancer (NSCLC), fusion of anaplastic lymphoma kinase (ALK) gene and EML4 gene promotes lung cancer cell growth, especially if they have adenocarcinoma subtype of lung cancer.
In a recent Nature Medicine paper, Bivonas lab homed in on a form of malignant lung cancer that stems from a gene fusion, where the EML4 and ALK genes get squished together in a tumor-triggering conformation.
2] Human genes: EGFR, epidermal growth factor receptor; KRAS, kirsten rat sarcoma viral oncogene homolog; ERBB2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; EML4, echinoderm microtubule-associated protein like 4; ALK, anaplastic lymphoma receptor tyrosine kinase; SEPT9, septin 9; CDKN2A, cyclin-dependent kinase inhibitor 2A; MET, MET proto-oncogene, receptor tyrosine kinase; CDK6, cyclin-dependent kinase 6; BRAF, B-Raf proto-oncogene, serine/threonine kinase.
5] Human genes: ERBB2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (also known as HER2); EGFR, epidermal growth factor receptor; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; BRAF, v-raf murine sarcoma viral oncogene homolog B1; ALK, anaplastic lymphoma receptor tyrosine kinase; EML4, echinoderm microtubule associated protein; NPM1, nucleophosmin (nucleolar phosphoprotein B23, numatrin); VCL, vinculin; TPM3, tropomyosin 3; TPM4, tropomyosin 4; KIT, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; BRCA1, breast cancer 1, early onset; BRCA2, breast cancer 2, early onset.
4] Human genes: BCR, breakpoint cluster region; ABL, Abelson tyrosine kinase; EML4, echinoderm microtubule associated protein like 4; ALK, anaplastic lymphoma receptor tyrosine kinase; EGFR, epidermal growth factor receptor; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; BRAF, v-raf murine sarcoma viral oncogene homolog B1; NRAS, neuroblastoma RAS viral (v-ras) oncogene homolog; KIT, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha.
The breakpoint of ALK is highly conservative and located at exon 20, with various breakpoints in the amino terminal of EML4, leading to different EML4-ALK fusion variants.
6 July 2011 - US-based antibody products manufacturer Cell Signaling Technology Inc (CST) said today that it has signed an agreement with Pfizer Inc (NYSE: PFE) that provides Pfizer with a worldwide non-exclusive licence under the patent estates pooled by CST and Astellas Pharma Inc (Patent Estates) relating to EML4 anaplastic lymphoma kinase (ALK).